Raining all weekend, which is perfect to stay home and catch up on #ASH22 abstracts. I still like to print them out and read! Which abstracts are exciting to you this year?

CONGRESS | #ASH22 Mina Abdelmalek Mina Abdelmalek of UBuffalo presents data suggesting improved MRD negative CR and lower relapse rates in patients with intermediate-risk ND AML treated with gemtuzumab ozogamicin (GO) plus 7+3 (n = 33) induction vs 7+3 alone (n = 80). #leusm

CONGRESS | #ASH22 Mina Abdelmalek Mina Abdelmalek describes CR/CRi rate = 82% for GO plus 7+3 vs 55% for 7+3. Post-CR/CRi relapse rate was 11% for GO plus 7+3 vs 44% for 7+3. #leusm

Congrats ⁦Arya Roy⁩ presenting our work demonstrating the impact of race on mortality in TTP ⁦Roswell Park⁩ #ASH22

This is in #BuffaloNY just a block away from Roswell Park - absolutely insane. I walked over here and I’ve never experienced such a storm in my lifetime. Kudos to the nurses, physicians, and other staff members who have been stuck in the hospital since THURSDAY! #Blizzardof2022

In the final entry of our top 10 blogs of 2022, we share the story of Kevin and Marilyn, a couple who shared everything in their 30 years together but never imagined they'd share a cancer diagnosis. roswellpark.org/cancertalk/202…

Please don’t share the video of the Damar Hamlin play. Share this because we are all Praying for him and his family.

Niagara Falls will be illuminated blue tonight in support of Damar Hamlin and the Buffalo Bills from 9-9:15 p.m. 💙 𝐃𝐚𝐦𝐚𝐫 𝐇𝐚𝐦𝐥𝐢𝐧 📸: Instagrammer imagesbyreuben

Marilyn & Kevin Sittniewski are celebrating the decades they've had building a life together. They have two beautiful daughters, a tight-knit family, friends they travel to visit. They’ve shared a lot, but they never expected to both be leukemia survivors. bit.ly/Roswell_Marily…

I'm excited to be a part of the 27th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma! Register today and join me February 23-26, 2023 in Miami Beach or virtually! app.ingo.me/q/kc3sd #GoToPER #WinterHem23

Privileged to be part of this effort Journal of Clinical Oncology investigating Magrolimab in MDS. Eagerly awaiting ENHANCE- Hopeful for a paradigm shift in mgmt of MDS. Naval Daver, M.D. Eunice Wang MD Terrence Bradley Daniel Pollyea G Garcia-Manero Rami komrokji Hagop Kantarjian,MD ascopubs.org/doi/full/10.12….

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk #MDS : - ORR : 75 % , CR : 33 % - PFS : 11.6 mo , mOS not reached - In TP53-mutant pts, 40% achieved CR with median OS of 16.3 mo. - 36% pts had allo SCT with 77% 2-yr OS ascopubs.org/doi/full/10.12…

The Women in Leukemia podcast series won a Hermes Creative Award! Thank you OncLive.com for supporting this idea and to Azra Raza SelinaLuger gail roboz Eunice Wang MD Jessica Altman, MD Judy Karp, Michelle LeBeau, Wendy Stock and Courtney Dinardo for your stories! tinyurl.com/yxh6ywv8

Eunice S. Wang, MD, and Gregory Roloff, MD, and on B-ALL: Outcomes With Brexucabtagene Autoleucel in Adult Patients ascopost.com/videos/2023-as… #ASCO23 #leusm #leukemia #hematology Eunice Wang MD Roswell Park Greg Roloff University of Chicago Hematology/Oncology UChicagoCancerCenter

Great talk by Steven Green Roswell Park discussing one of the highest unmet needs in AML- Newly Dx Secondary AML after previous exposure to HMA’s. We will be opening TAGALONG study soon specifically in this patient population 👇Eunice Wang MD DAVA Oncology #DAVABermudaHeme

Thrilled to have this work published in Blood Cancer Journal! Thank you Eunice Wang MD for your outstanding mentorship! Roswell Park Leukemia Mina Abdelmalek Amanda Przespolewski, DO Jeff Baron, PharmD, BCOP, DPLA Faisal, Salman M Mark Faber Matthew Gravina, MD Roswell Park Roswell Park Hematology/Oncology Fellowship nature.com/articles/s4140…

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-00... sciencedirect.com/science/articl… #KMT2A #MENIN #NPM1 Eunice Wang MD Mayo Clinic Comprehensive Cancer Center

Proud to co-lead distinguished group of leukemia MDs on this first trial of ziftomenib (KO539) menin inhibitor therapy for NPM1 mutant R/RAML

Such an important step forward for our AML patients who are fighting this aggressive disease! Congratulations to everyone who worked hard to make this possible most of all our patients & caregivers who do the impossible every day by keeping the faith. 🪔👊🏽💪🏼

A giant step forward with the first approval of menin inhibitors! Beyond an exciting achievement for our patients and the AML field! Congratulations to all who have contributed! The future is ☀️ with menin inhibitors in the future! 👏👏👏